DOI: 10.1515/mr-2024-0056
Combining transcriptomic and metabolomic insights to guide the clinical application of adipose-and bone marrow-derived mesenchymal stem cells
Wenyan Zhou1
Junxin Lin2
David C.Hay3
Xudong Yao4
Hongwei Ouyang5
1.School of Medicine,Taizhou University,Taizhou,Zhejiang,China;Dr.Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China2.School of Medicine,Taizhou University,Taizhou,Zhejiang,China3.Centre for Regenerative Medicine,Institute for Regeneration and Repair,University of Edinburgh,Edinburgh,UK4.International School of Medicine,International Institutes of Medicine,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Yiwu,Zhejiang,China5.Department of Sports Medicine of the Second Affiliated Hospital,and Liangzhu Laboratory,Zhejiang University School of Medicine,Hangzhou,310058,China;Dr.Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine,Zhejiang University School of Medicine,Hangzhou,310058,Zhejiang,China
摘要：Adipose-derived mesenchymal stem cells(ADSCs)and bone marrow-derived mesenchymal stem cells(BMSCs)have shown great potential in clinical applications.Howev-er,the similarities and differences between these two cell types have not been fully elucidated.Recent advances in transcriptomic and metabolomic research have provided valuable insight into the characteristics and functions of ADSCs and BMSCs.In this perspective article,we review the key findings from these studies,including cellular het-erogeneity as well as differences in metabolic and secretory properties.We discuss how these insights can help guide the selection of the most suitable cell source for the clinic,and the optimization of preconditioning strategies prior to clinical deployment.Furthermore,we analyze the current landscape of products and clinical trials involving ADSCs and BMSCs,highlighting their therapeutic potential.We propose that the integration of multi-omics datasets will be crucial for establishing a comprehensive understanding of ADSC and BMSC identity and potency,and the provision of quality-assured stem cell-derived products for the clinic.
机标关键词：applicationinsightsclinicalguidestemcellsadipose-andbone
论文发表日期：2025-02-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：7( 76-82 )
英文信息